Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects

por Guérard, N., Morand, O., Dingemanse, J.
Publicado 2017

Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types

por Welford, R W D, Mühlemann, A, Garzotti, M, Rickert, V, Groenen, P M A, Morand, O, Üçeyler, N, Probst, M R
Publicado 2018